|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DYNC1I1 |
Gene summary for DYNC1I1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DYNC1I1 | Gene ID | 1780 |
| Gene name | dynein cytoplasmic 1 intermediate chain 1 | |
| Gene Alias | DNCI1 | |
| Cytomap | 7q21.3 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | A4D1I7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1780 | DYNC1I1 | AEH-subject1 | Human | Endometrium | AEH | 4.00e-03 | 2.52e-01 | -0.3059 |
| 1780 | DYNC1I1 | AEH-subject5 | Human | Endometrium | AEH | 6.90e-12 | 5.27e-01 | -0.2953 |
| 1780 | DYNC1I1 | EEC-subject1 | Human | Endometrium | EEC | 1.13e-06 | 3.30e-01 | -0.2682 |
| 1780 | DYNC1I1 | EEC-subject2 | Human | Endometrium | EEC | 2.71e-02 | -1.21e-01 | -0.2607 |
| 1780 | DYNC1I1 | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 3.68e-03 | 6.21e-02 | -0.1875 |
| 1780 | DYNC1I1 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 1.08e-02 | 1.39e-01 | -0.1883 |
| 1780 | DYNC1I1 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 2.22e-05 | -6.57e-02 | -0.1916 |
| 1780 | DYNC1I1 | LZE4T | Human | Esophagus | ESCC | 1.70e-03 | 1.42e-01 | 0.0811 |
| 1780 | DYNC1I1 | LZE7T | Human | Esophagus | ESCC | 2.56e-05 | 2.84e-01 | 0.0667 |
| 1780 | DYNC1I1 | LZE24T | Human | Esophagus | ESCC | 2.20e-04 | 1.50e-01 | 0.0596 |
| 1780 | DYNC1I1 | P2T-E | Human | Esophagus | ESCC | 7.28e-26 | 4.18e-01 | 0.1177 |
| 1780 | DYNC1I1 | P4T-E | Human | Esophagus | ESCC | 1.49e-09 | 2.35e-01 | 0.1323 |
| 1780 | DYNC1I1 | P5T-E | Human | Esophagus | ESCC | 1.96e-05 | 1.07e-01 | 0.1327 |
| 1780 | DYNC1I1 | P10T-E | Human | Esophagus | ESCC | 1.57e-53 | 9.23e-01 | 0.116 |
| 1780 | DYNC1I1 | P12T-E | Human | Esophagus | ESCC | 3.41e-36 | 8.13e-01 | 0.1122 |
| 1780 | DYNC1I1 | P15T-E | Human | Esophagus | ESCC | 6.21e-15 | 3.61e-01 | 0.1149 |
| 1780 | DYNC1I1 | P16T-E | Human | Esophagus | ESCC | 4.40e-09 | 1.92e-01 | 0.1153 |
| 1780 | DYNC1I1 | P17T-E | Human | Esophagus | ESCC | 4.79e-04 | 2.06e-01 | 0.1278 |
| 1780 | DYNC1I1 | P20T-E | Human | Esophagus | ESCC | 1.03e-23 | 4.98e-01 | 0.1124 |
| 1780 | DYNC1I1 | P23T-E | Human | Esophagus | ESCC | 6.53e-09 | 2.14e-01 | 0.108 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00516568 | Endometrium | AEH | establishment of organelle localization | 77/2100 | 390/18723 | 4.89e-07 | 1.94e-05 | 77 |
| GO:00307058 | Endometrium | AEH | cytoskeleton-dependent intracellular transport | 38/2100 | 195/18723 | 4.72e-04 | 4.91e-03 | 38 |
| GO:00516507 | Endometrium | AEH | establishment of vesicle localization | 32/2100 | 161/18723 | 8.99e-04 | 8.24e-03 | 32 |
| GO:00516487 | Endometrium | AEH | vesicle localization | 32/2100 | 177/18723 | 4.33e-03 | 2.86e-02 | 32 |
| GO:005165613 | Endometrium | EEC | establishment of organelle localization | 75/2168 | 390/18723 | 6.23e-06 | 1.49e-04 | 75 |
| GO:003070514 | Endometrium | EEC | cytoskeleton-dependent intracellular transport | 39/2168 | 195/18723 | 4.40e-04 | 4.58e-03 | 39 |
| GO:005165013 | Endometrium | EEC | establishment of vesicle localization | 31/2168 | 161/18723 | 2.99e-03 | 2.10e-02 | 31 |
| GO:005165617 | Esophagus | ESCC | establishment of organelle localization | 273/8552 | 390/18723 | 9.13e-23 | 1.81e-20 | 273 |
| GO:005165016 | Esophagus | ESCC | establishment of vesicle localization | 114/8552 | 161/18723 | 8.20e-11 | 2.53e-09 | 114 |
| GO:003070518 | Esophagus | ESCC | cytoskeleton-dependent intracellular transport | 133/8552 | 195/18723 | 1.48e-10 | 4.27e-09 | 133 |
| GO:001097013 | Esophagus | ESCC | transport along microtubule | 107/8552 | 155/18723 | 3.17e-09 | 6.80e-08 | 107 |
| GO:005164815 | Esophagus | ESCC | vesicle localization | 119/8552 | 177/18723 | 5.16e-09 | 1.08e-07 | 119 |
| GO:00723846 | Esophagus | ESCC | organelle transport along microtubule | 65/8552 | 85/18723 | 6.61e-09 | 1.35e-07 | 65 |
| GO:00474962 | Esophagus | ESCC | vesicle transport along microtubule | 36/8552 | 47/18723 | 1.53e-05 | 1.38e-04 | 36 |
| GO:00991114 | Esophagus | ESCC | microtubule-based transport | 115/8552 | 190/18723 | 2.54e-05 | 2.15e-04 | 115 |
| GO:00995185 | Esophagus | ESCC | vesicle cytoskeletal trafficking | 50/8552 | 73/18723 | 6.75e-05 | 5.12e-04 | 50 |
| GO:005165621 | Liver | HCC | establishment of organelle localization | 226/7958 | 390/18723 | 4.15e-10 | 1.34e-08 | 226 |
| GO:005165021 | Liver | HCC | establishment of vesicle localization | 103/7958 | 161/18723 | 2.94e-08 | 6.69e-07 | 103 |
| GO:005164821 | Liver | HCC | vesicle localization | 107/7958 | 177/18723 | 1.05e-06 | 1.57e-05 | 107 |
| GO:00723843 | Liver | HCC | organelle transport along microtubule | 56/7958 | 85/18723 | 1.13e-05 | 1.29e-04 | 56 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0513226 | Endometrium | AEH | Salmonella infection | 71/1197 | 249/8465 | 1.69e-09 | 3.44e-08 | 2.52e-08 | 71 |
| hsa0414524 | Endometrium | AEH | Phagosome | 41/1197 | 152/8465 | 2.12e-05 | 2.22e-04 | 1.63e-04 | 41 |
| hsa048144 | Endometrium | AEH | Motor proteins | 42/1197 | 193/8465 | 2.41e-03 | 1.42e-02 | 1.04e-02 | 42 |
| hsa05132112 | Endometrium | AEH | Salmonella infection | 71/1197 | 249/8465 | 1.69e-09 | 3.44e-08 | 2.52e-08 | 71 |
| hsa04145111 | Endometrium | AEH | Phagosome | 41/1197 | 152/8465 | 2.12e-05 | 2.22e-04 | 1.63e-04 | 41 |
| hsa0481411 | Endometrium | AEH | Motor proteins | 42/1197 | 193/8465 | 2.41e-03 | 1.42e-02 | 1.04e-02 | 42 |
| hsa0513227 | Endometrium | EEC | Salmonella infection | 71/1237 | 249/8465 | 7.11e-09 | 1.30e-07 | 9.69e-08 | 71 |
| hsa0414525 | Endometrium | EEC | Phagosome | 42/1237 | 152/8465 | 2.01e-05 | 2.28e-04 | 1.70e-04 | 42 |
| hsa048142 | Endometrium | EEC | Motor proteins | 42/1237 | 193/8465 | 4.43e-03 | 2.39e-02 | 1.78e-02 | 42 |
| hsa0513236 | Endometrium | EEC | Salmonella infection | 71/1237 | 249/8465 | 7.11e-09 | 1.30e-07 | 9.69e-08 | 71 |
| hsa0414534 | Endometrium | EEC | Phagosome | 42/1237 | 152/8465 | 2.01e-05 | 2.28e-04 | 1.70e-04 | 42 |
| hsa048143 | Endometrium | EEC | Motor proteins | 42/1237 | 193/8465 | 4.43e-03 | 2.39e-02 | 1.78e-02 | 42 |
| hsa05132211 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
| hsa0414530 | Esophagus | ESCC | Phagosome | 100/4205 | 152/8465 | 3.81e-05 | 1.72e-04 | 8.82e-05 | 100 |
| hsa0496223 | Esophagus | ESCC | Vasopressin-regulated water reabsorption | 33/4205 | 44/8465 | 5.27e-04 | 1.78e-03 | 9.13e-04 | 33 |
| hsa05132310 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
| hsa04145114 | Esophagus | ESCC | Phagosome | 100/4205 | 152/8465 | 3.81e-05 | 1.72e-04 | 8.82e-05 | 100 |
| hsa0496233 | Esophagus | ESCC | Vasopressin-regulated water reabsorption | 33/4205 | 44/8465 | 5.27e-04 | 1.78e-03 | 9.13e-04 | 33 |
| hsa0513242 | Liver | HCC | Salmonella infection | 178/4020 | 249/8465 | 5.90e-15 | 1.98e-13 | 1.10e-13 | 178 |
| hsa0414521 | Liver | HCC | Phagosome | 93/4020 | 152/8465 | 4.27e-04 | 1.88e-03 | 1.05e-03 | 93 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DYNC1I1 | SNV | Missense_Mutation | novel | c.1025N>G | p.Ser342Cys | p.S342C | O14576 | protein_coding | deleterious(0.01) | possibly_damaging(0.474) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| DYNC1I1 | SNV | Missense_Mutation | novel | c.1188N>A | p.Asn396Lys | p.N396K | O14576 | protein_coding | tolerated(0.23) | benign(0.015) | TCGA-A2-A0CR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| DYNC1I1 | SNV | Missense_Mutation | c.933N>T | p.Glu311Asp | p.E311D | O14576 | protein_coding | tolerated(0.23) | benign(0.026) | TCGA-A8-A09M-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | CR | |
| DYNC1I1 | SNV | Missense_Mutation | c.1909N>A | p.Glu637Lys | p.E637K | O14576 | protein_coding | deleterious(0.02) | benign(0.218) | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD | |
| DYNC1I1 | SNV | Missense_Mutation | c.1500N>A | p.Asp500Glu | p.D500E | O14576 | protein_coding | deleterious(0.01) | probably_damaging(0.951) | TCGA-AR-A1AI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | PD | |
| DYNC1I1 | SNV | Missense_Mutation | novel | c.799N>T | p.Val267Phe | p.V267F | O14576 | protein_coding | tolerated(0.08) | benign(0.017) | TCGA-AR-A24H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
| DYNC1I1 | SNV | Missense_Mutation | novel | c.760G>C | p.Asp254His | p.D254H | O14576 | protein_coding | deleterious(0) | probably_damaging(0.967) | TCGA-AR-A250-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| DYNC1I1 | SNV | Missense_Mutation | rs201114371 | c.448N>A | p.Val150Met | p.V150M | O14576 | protein_coding | tolerated(0.81) | benign(0.044) | TCGA-EW-A423-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
| DYNC1I1 | SNV | Missense_Mutation | c.830N>A | p.Arg277His | p.R277H | O14576 | protein_coding | deleterious(0.03) | possibly_damaging(0.53) | TCGA-Z7-A8R5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| DYNC1I1 | insertion | Frame_Shift_Ins | novel | c.1581_1582insA | p.Phe528IlefsTer2 | p.F528Ifs*2 | O14576 | protein_coding | TCGA-A8-A06P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |